Clinical trial
Phase II Bevacizumab + Tax In Advanced Breast Cancer
NCT00027885 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00027885 |
|---|---|
| Title | Phase II Bevacizumab + Tax In Advanced Breast Cancer |
| Official title | A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | bevacizumab, cyclophosphamide, docetaxel, doxorubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy |
| Enrollment | 49 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Aug 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: